Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

<p>Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.</p>

Saved in:

書目詳細資料
主要作者:	Amr El Zawily (14851115) (author)
其他作者:	Frederick S. Vizeacoumar (14851118) (author), Renuka Dahiya (14851121) (author), Sara L. Banerjee (14851124) (author), Kalpana K. Bhanumathy (14851127) (author), Hussain Elhasasna (14851130) (author), Glinton Hanover (14851133) (author), Jessica C. Sharpe (14851136) (author), Malkon G. Sanchez (14851139) (author), Paul Greidanus (14851142) (author), R. Greg Stacey (14851145) (author), Kyung-Mee Moon (14851148) (author), Ilya Alexandrov (14851151) (author), Juha P. Himanen (14851154) (author), Dimitar B. Nikolov (14851157) (author), Humphrey Fonge (14851160) (author), Aaron P. White (14851163) (author), Leonard J. Foster (8976302) (author), Bingcheng Wang (14851166) (author), Behzad M. Toosi (14851169) (author), Nicolas Bisson (14851172) (author), Tajib A. Mirzabekov (14851175) (author), Franco J. Vizeacoumar (14851178) (author), Andrew Freywald (14851181) (author)
出版:	2025
主題:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Computational Methods Database resources Drug Targets Cell surface receptor drug targets Proteomics Systems Biology Translational Research
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
由: Amr El Zawily (14851115)
出版: (2025)

Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
由: Amr El Zawily (14851115)
出版: (2025)

Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
由: Amr El Zawily (14851115)
出版: (2025)

Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
由: Amr El Zawily (14851115)
出版: (2025)

Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
由: Amr El Zawily (14851115)
出版: (2025)

Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
由: Amr El Zawily (14851115)
出版: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
由: Yuncheng Bei (16546095)
出版: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
由: Yuncheng Bei (16546095)
出版: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
由: Yuncheng Bei (16546095)
出版: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
由: Katie E. Hebron (15046889)
出版: (2025)

Supplemental Figure 2 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
由: William C. Reinhold (16015934)
出版: (2025)

Supplementary Figure 1 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
由: William C. Reinhold (16015934)
出版: (2025)

Supplementary Table 1 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
由: William C. Reinhold (16015934)
出版: (2025)

Supplementary Table 2 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
由: William C. Reinhold (16015934)
出版: (2025)

Supplementary Table 3 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
由: William C. Reinhold (16015934)
出版: (2025)

Supplementary Table 4 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
由: William C. Reinhold (16015934)
出版: (2025)

Supplementary Table 5 from CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations
由: William C. Reinhold (16015934)
出版: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
由: Srivandana Akshintala (16610490)
出版: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
由: Srivandana Akshintala (16610490)
出版: (2025)

Figure S1 from Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR
由: Jeffrey D. Mandell (14963909)
出版: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
由: Zev A. Wainberg (15047031)
出版: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
由: Yuanqing Ma (15052437)
出版: (2025)

FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
由: Jonathan Chou (14957015)
出版: (2025)

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
由: Jonathan Chou (14957015)
出版: (2025)

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
由: Jonathan Chou (14957015)
出版: (2025)

FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
由: Jonathan Chou (14957015)
出版: (2025)

FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
由: Jonathan Chou (14957015)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_n4au7hbgrmjq0b19ru5ekg5a8f